-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Tissue Factor(TF) and Tissue Factor Pathway Inhibitor(TFPI) in Cancer Associated Thrombosis

Symposia: Scientific Workshop on Interplay Between Coagulation and Malignancy Program: Scientific Workshops
Friday, December 6, 2024: 2:05 PM-3:05 PM
Room 24 (San Diego Convention Center)
Moderator:
and Alan E. Mast, MD, PhD, Versiti
Disclosures:
Mast: Novo Nordisk: Consultancy, Research Funding; Pharmacosmos: Research Funding.
The session focuses on the complex relationship between tissue factor and tissue factor pathway inhibitor(TFPI) in contributing to the prothrombotic state of malignancy.
Moderator Introduction

Alan E. Mast, MD, PhD

Blood Center of Wisconsin, Versiti, Milwaukee, WI
Tissue Factor Pathway Inhibitor As Biomarker in Cancer Associated Thrombosis

Florian Moik, MD, PhD

Department of Internal Medicine, Division of Oncology, Medical University of Graz, Graz, Austria
Inactivation of Tissue Factor Pathway Inhibitor

Rory R. Koenen

CARIM - Biochemistry, Maastricht University, Maastricht, Netherlands
mir-5683 Inhibition Endothelial Tissue Factor Pathway Inhibitor in Cancer

Irene Martínez-Martínez, PhD

BioMedical Research Institute of Murcia (IMIB-Pascual Parrilla), Murcia, Spain
Mouse Xenograft Models of Acute Promyelocytic Leukemia and Coagulopathy

Yohei Hisada, PhD

University of North Carolina at Chapel Hill, Chapel Hill, NC
Panel Discussion
See more of: Scientific Workshop on Interplay Between Coagulation and Malignancy
See more of: Scientific Workshops
<< Previous Session | Next Session >>